Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership
11:51am, Wednesday, 22'nd Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Ar
Bank of America Corp DE Increases Stake in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
08:52am, Tuesday, 21'st Apr 2020
Bank of America Corp DE raised its position in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 14.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange C
Here’s Why We’re Not Too Worried About Kiniksa Pharmaceuticals’s (NASDAQ:KNSA) Cash Burn Situation
11:57am, Monday, 20'th Apr 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Kiniksa Pharmaceuticals (KNSA) - Research Analysts' Weekly Ratings Changes
06:10am, Monday, 20'th Apr 2020
Kiniksa Pharmaceuticals (NASDAQ: KNSA) recently received a number of ratings updates from brokerages and research firms: 4/11/2020 – Kiniksa Pharmaceuticals was downgraded by analysts at Zacks Inves
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Lowered to Hold at Zacks Investment Research
05:42am, Saturday, 11'th Apr 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Saturday, Zacks.com reports. According to
Kiniksa's Unexpected Play
06:07pm, Thursday, 09'th Apr 2020
Kiniksa announced an unexpected move into the COVID-19 furore. Kiniksa’s mavrilimumab demonstrates intriguing preliminary activity in a small group of 6 COVID-1
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Upgraded to Buy at Zacks Investment Research
07:30am, Thursday, 09'th Apr 2020
Kiniksa Pharmaceuticals (NASDAQ:KNSA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. Th
Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?
03:30pm, Wednesday, 08'th Apr 2020
Is (KNSA) Outperforming Other Medical Stocks This Year?
Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?
03:30pm, Wednesday, 08'th Apr 2020
Is (KNSA) Outperforming Other Medical Stocks This Year?
Coronavirus Stocks Gain: Vir Biotech up 26.6%; Kiniksa off 0.7%
11:45pm, Monday, 06'th Apr 2020
Shares of companies known to be pursuing coronavirus treatments were higher Monday amid a broad market rally. Among notable coronavirus stocks, 26 rose while 4 fell. The World Health Organization ha
3 Healthcare Stocks Fighting the Coronavirus
12:29pm, Monday, 06'th Apr 2020
It’s a new week, and market watchers are bracing themselves for whatever comes their way. Ahead of the opening bell on Monday U.S. stock futures are up, some welcome news after stocks rounded out th
Citigroup Inc. Has $31,000 Stake in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)
09:06am, Sunday, 05'th Apr 2020
Citigroup Inc. boosted its holdings in shares of Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) by 138.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exc
Company News for Apr 1, 2020
01:04pm, Wednesday, 01'st Apr 2020
Companies In The News Are: KNSA, EYEG, VBIV, EYES
Company News for Apr 1, 2020
01:04pm, Wednesday, 01'st Apr 2020
Companies In The News Are: KNSA, EYEG, VBIV, EYES
Oppenheimer sees 26% downside in Intuitive Surgical in premarket action
11:51am, Wednesday, 01'st Apr 2020
Apellis Pharmaceuticals (NASDAQ:APLS) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James.BioXcel Therapeutics (NASDAQ:BTAI) initiated with Buy rating and $45 (101% up
